- AU$9.53m
- AU$9.10m
- AU$1.78m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 4.69 | ||
Price to Tang. Book | 4.69 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 5.34 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -157.45% | ||
Return on Equity | -273.13% | ||
Operating Margin | -295.76% |
Financial Summary
Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | AU$m | 3.85 | 3.99 | 2.76 | 3.53 | 1.78 | n/a | n/a | -13.04% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
AdAlta Limited is an Australia-based clinical-stage biotechnology company. The Company uses its i-body platform to discover and develop protein therapeutics addressing drug targets that are challenging for other technologies. The Company's first-in-class lead asset, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target, CXCR4. It is also engaged in developing i-body enabled Chimeric antigen receptor T cell (CAR-T) cells. It co-develops i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs.
Directors
- Paul MacLeman CHM
- Timothy Oldham CEO
- Dallas Hartman COO
- Michael Foley CSO
- Kate Griffiths OTH
- Cameron Jones SEC
- Elizabeth McCall DRC
- James Williams DRC
- David Fuller NED
- Robert Peach NED (62)
- Rosalind Wilson NED
- Last Annual
- June 30th, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- June 22nd, 2006
- Public Since
- August 22nd, 2016
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS
- Shares in Issue
- 595,623,520

- Address
- Unit 15 / 2 Park Drive, Bundoora, MELBOURNE, 3083
- Web
- https://adalta.com.au/
- Phone
- +61 394795159
- Auditors
- Dry Kirkness
Upcoming Events for 1AD
Similar to 1AD
Actinogen Medical
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
Anteotech
Australian Stock Exchange - SEATS
FAQ
As of Today at 18:04 UTC, shares in Adalta are trading at AU$0.02. This share price information is delayed by 15 minutes.
Shares in Adalta last closed at AU$0.02 and the price had moved by -23.81% over the past 365 days. In terms of relative price strength the Adalta share price has underperformed the ASX All Ordinaries Index by -32.21% over the past year.
The overall consensus recommendation for Adalta is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAdalta does not currently pay a dividend.
Adalta does not currently pay a dividend.
Adalta does not currently pay a dividend.
To buy shares in Adalta you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.02, shares in Adalta had a market capitalisation of AU$9.53m.
Here are the trading details for Adalta:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: 1AD
Based on an overall assessment of its quality, value and momentum Adalta is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Adalta is AU$0.18. That is 1025% above the last closing price of AU$0.02.
Analysts covering Adalta currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adalta. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -29.25%.
As of the last closing price of AU$0.02, shares in Adalta were trading -27.8% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Adalta PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Adalta's management team is headed by:
- Paul MacLeman - CHM
- Timothy Oldham - CEO
- Dallas Hartman - COO
- Michael Foley - CSO
- Kate Griffiths - OTH
- Cameron Jones - SEC
- Elizabeth McCall - DRC
- James Williams - DRC
- David Fuller - NED
- Robert Peach - NED
- Rosalind Wilson - NED